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Background: Three-dimensional (3D) hydrogel-based stem cell therapies contribute to enhanced therapeutic efficacy
in treating diseases, and determining the optimal mechanical strength of the hydrogel in vivo is important for therapeutic
success. We evaluated the proliferation of human neural stem cells incorporated within in situ-forming hydrogels and
compared the effect of hydrogels with different elastic properties in cell/hydrogel-xenografted mice.
Methods: The gelatin-polyethylene glycol-tyramine (GPT) hydrogel was fabricated through enzyme-mediated
cross-linking reaction using horseradish peroxidase (HRP) and hydrogen peroxide (H2O2).
Results: The F3-effluc encapsulated within a soft 1,800 pascal (Pa) hydrogel and stiff 5,800 Pa hydrogel proliferated
vigorously in a 24-well plate until day 8. In vitro and in vivo kinetics of luciferase activity showed a slow time-to-peak
after D-luciferin administration in the stiff hydrogel. When in vivo proliferation of F3-effluc was observed up to day 21 in
both the hydrogel group and cell-only group, F3-effluc within the soft hydrogel proliferated more vigorously, compared
to the cells within the stiff hydrogel. Ki-67-specific immunostaining revealed highly proliferative F3-effluc with
compactly distributed cell population inside the 1,800 Pa or 5,800 Pa hydrogel.
Conclusions: We examined the in vivo effectiveness of different elastic types of hydrogels encapsulating viable
neural stem cells by successfully monitoring the proliferation of implanted stem cells incorporated within a 3D
hydrogel scaffold.
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Optical kineticsBackground
Rapid advances in stem cell-based therapy have opened
up the possibility of stem cell use to reconstitute injured
tissues for the functional improvement in the clinic. Par-
ticularly, neural stem cells, capable of being differenti-
ated into functional neurons, could become a good cell
source for the treatment of neurodegenerative diseases
[1-4]. In spite of this progress, studies concerning stem
cell therapy have shown poor survival rates for the im-
planted stem cells, owing to the necrotic environment of* Correspondence: kdp@ajou.ac.kr; dsl@snu.ac.kr
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in any medium, provided the original work is pthe injured and inflamed tissues. This remains a critical
limitation for successful cell therapy. To overcome this
challenge, a variety of biomaterials such as microfiber-
type or gel-type scaffolds have been developed to support
survival and proliferation of implanted stem cells [5-11].
Among the many scaffolds currently available, hydrogels,
capable of imbibing large amounts of water and possessing
suitable physicochemical properties, are known to exhibit
the best biocompatibility and biodegradability in vivo. The
hydrogel materials can be fabricated by various chemical
and physical reactions, and their physiochemical proper-
ties, such as gelation, mechanical properties, and degrad-
ation time, could be easily controlled [12,13]. In addition,
the hydrogels can encapsulate therapeutic drugs and cells
for the treatment of targeted diseases as they are formedan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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facilitated the use of hydrogels in therapeutic cell implants
or as therapeutic delivery vehicles [14-16]. Hydrogels,
which are cross-linked hydrophilic polymers, can serve as
a bio-artificial niche not only for promoting survival of the
implanted cells, but also for protection of the cells from
the damaged tissue environment in vivo, by providing
mechanical framework and three-dimensional super-
porous structures. The matrix hydrogel elasticity could
be adjusted to match the stiffness of real tissues (brain:
0.1 to 1 kilopascal [kPa]; muscle: 8 to 17 kPa; collage-
nous bone: >34 kPa) and optimized to induce specific
cell fates from the implanted mesenchymal stem cells
[17-19]. Furthermore, studies have shown that hydrogel-
encapsulated cells were functionally effective in several
disease models [11,20,21]. Despite this effectiveness of
the biomimetic hydrogel, the characteristics of different
in vivo hydrogels are not understood for their real in vivo
behavior of hydrogel-encapsulated cells. An in vivo im-
aging technique that tracks the survival of implanted stem
cells within the hydrogel will help evaluate the in vivo
efficacy of different hydrogel matrix types.
The gelatin-polyethylene glycol-tyramine (GPT) hydrogel,
recently developed in our group, is an in situ cross-linkable
hydrogel that exhibits rapid gel formation induced by the
cross-linking reaction of horseradish peroxidase (HRP) with
hydrogen peroxide (H2O2) [22]. This enzyme-mediated
type of hydrogel possesses significant advantages of
excellent biocompatibility and controllable mechanical
strength. In addition, because this hydrogel is compat-
ible with an injection system that can easily be applied
in vivo, with minimal surgical invasiveness, it has the
potential for use in tissue engineering-based regenera-
tive therapy [22,23].
Bioluminescence light is emitted from the catalytic
reaction of luciferase enzyme with its substrate, and
in vivo administration of D-luciferin can be used to gen-
erate bioluminescence in implanted luciferase-expressing
stem cells encapsulated within the hydrogel in small an-
imals. The permeability of D-luciferin within the hydro-
gel may differ according to its mechanical strength.
Therefore, examining the in vivo kinetics of the lucifer-
ase activity in the living mouse bearing the hydrogel-
encapsulated stem cells after D-luciferin administration
is necessary to acquire the optimal bioluminescence sig-
nal in implanted stem cells within hydrogels of different
elasticity.
In this study, we investigated the survival and prolifer-
ation of injectable hydrogel-encapsulated stem cells by
non-invasively monitoring human neural stem cells car-
rying the highly sensitive luciferase gene. Based on this
in vivo imaging strategy, cell survival and proliferation in
soft and stiff hydrogels were evaluated in nude mice with
analysis of in vivo kinetics of the luciferase substrate.Methods
Synthesis of GPT conjugate
In our previous report, the GPT hydrogel was developed
as an injectable material with excellent biocompatibility
and bioactivity for tissue regeneration and drug delivery
[22]. The GPT conjugate was synthesized by coupling tyr-
amine (TA)-conjugated polyethylene glycol (PNC-PEG-TA)
and gelatin. Briefly, the hydroxyl groups of polyethylene gly-
col (PEG) reacted with p-nitrophenyl chloroformate (PNC)
to activate the terminal groups (PNC-PEG-PNC), and then
the PNC-PEG-PNC reacted with TA and gelatin to give the
GPT polymer. The chemical structure and degree of substi-
tution (DS) of TA were characterized by 1H NMR and UV
measurements (1H NMR (D2O): δ 4.8 (m, the proton
of anomeric carbon of gelatin), δ 0.8 to 4.6 (m, alkyl
proton of gelatin), δ 3.5 to 3.8 (m, -CH2-CH2 of PEG
ethylene), and δ 6.8 and 7.1 (m, aromatic protons of
TA)). The TA content in the polymer was determined by
UV-vis spectroscopy measurements at a wavelength of
275 nm. Utilizing a tyramine standard curve, we found
that the TA content in the GPT conjugate was 110 μmol/g
of GPT polymer. Gelatin (type A from porcine skin, >300
Bloom), PEG (MW 4,000), HRP (250 to 330 units/mg
solid), aqueous hydrogen peroxide (H2O2; 30% [w/w]),
4-dimethylamino pyridine (DMAP), and PNC were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). TA
was obtained from Acros Organics (Geel, Belgium).
Triethylamine (TEA) was supplied by Kanto Chemical
Corp. (Tokyo, Japan). Aluminum oxide (Al2O3) was pur-
chased from Strem Chemicals (Newburyport, MA, USA).
Other chemical reagents and solvents were used without
further purification.
Preparation of the hydrogels and measurement of the
elastic modulus (G′)
The GPT hydrogels (200 μL) were prepared through
enzyme-mediated reaction using HRP and H2O2. One-
hundred microliters of GPT polymer solution (3% w/w)
dissolved in HRP stock solution and another 100 μL dis-
solved in H2O2 solution (0.0038% to 0.0075% w/w) were
mixed to form the hydrogels. All solutions were dissolved
in 0.01 M phosphate-buffered saline (PBS; pH 7.4).
The elastic modulus (G′) was measured with an Ad-
vanced Rheometer GEM-150-050 (Bohlin Instruments,
East Brunswick, NJ, USA) using the parallel plate (20-mm
diameter) configuration at 37°C in oscillatory mode. The
GPT polymer was dissolved both in HRP solution
(0.0005 mg/mL of stock solution) and in solutions con-
taining different concentrations of H2O2 (0.0038% to
0.0075% w/w of stock solution). Two-hundred micro-
liter polymer solutions containing HRP and H2O2 were
rapidly mixed on the bottom plate of the instrument,
and the upper plate was immediately lowered down to
a measuring gap size of 1 mm. A frequency of 0.1 Hz
Hwang et al. EJNMMI Research 2014, 4:61 Page 3 of 11
http://www.ejnmmires.com/content/4/1/61(single frequency) and a strain of 0.1% (strain control)
were applied for the analysis to maintain a linear visco-
elastic response.
Cell culture and effluc virus infection
Use of fetal brain tissue collected for research was
approved by the Clinical Research Screening Committee
and the Internal Review Board (IRB) of the University of
British Columbia (for preparation of an immortalized
human neural stem cell line used in the present study).
V-myc oncogene-harbored F3 human neural stem cell
lines derived from 15-week-old fetal telencephalon peri-
ventricular layers [24,25] were maintained in Dulbecco's
modified Eagle's medium (DMEM, Invitrogen, Grand
Island, NY, USA) supplemented with 10% (v/v) fetal bo-
vine serum (Invitrogen, Grand Island, NY, USA) with 10
U/mL penicillin and 10 μg/mL streptomycin (Invitrogen,
Grand Island, NY, USA) in a humidified incubator at 37°C.
For in vivo visualization of grafted stem cells, F3 cells
were genetically engineered using a retroviral vector
(kindly provided by Dr. Brian Rabinovich of MD Anderson
Cancer Center). The backbone of the retroviral MSCV
DNA vector contains the enhanced firefly luciferase coding
gene (effluc; modified by the codon optimization tech-
nique) and Thy1.1 (CD90.1), which is linked with IRES
(internal ribosome entry site) and regulated by the cyto-
megalovirus (CMV) promoter in the 5′-LTR (long ter-
minal repeat) region. For retrovirus production, the viral
polyproteins (gag, pol, and env) were transfected into
293FT packaging cells. The F3 cells were infected with the
harvested viral supernatant in the presence of 10 mM
polybrene to prevent electrostatic repulsion between the
virus and cell membrane. F3 cells transfected with the en-
hanced firefly luciferase gene (F3-effluc) were separated by
magnetic-activated cell sorting (MACS) (Miltenyi Biotec
Ltd., Bisley, Surrey, UK) using monoclonal anti-CD90.1
microbeads. The purity of magnetically separated CD90.1+
F3-effluc cells was examined by fluorescence-activated cell
sorting (FACS) analysis (BD Immunocytometry System,
Becton Dickinson, Franklin Lakes, NJ, USA) using the
monoclonal antibody anti-CD90.1 conjugated to fluor-
escein isothiocyanate (FITC).
In vitro bioluminescence assay
After F3-effluc cells were mixed with hydrogels possessing
matrix strengths of 1,800 Pa (GPT 1.8 K) or 5,800 Pa
(GPT 5.8 K), the firefly luciferase activity was measured
in a 96-well plate (n = 3). In vivo D-luciferin (0.1 mL at
3 μg/μL) was directly treated into the cell/hydrogel mixture.
Simultaneous treatment of each group with D-luciferin was
carried out using a multipipette. The luciferase intensity
was measured using a microplate luminometer (TR717,
Applied Biosystems, Carlsbad, CA, USA) with an integra-
tion time of 20 s. The kinetics of the luciferase activityafter D-luciferin administration was examined in vitro
using a microplate luminometer for a period of 95 min
with 5-min intervals between measurements.
In vivo bioluminescence imaging in cell/hydrogel-bearing
nude mice
Mice were maintained without unnecessary pain or dis-
tress, and 8-week-old male BALB/c nude mice were used
for the in vivo hydrogel study. All animals were housed
under specific pathogen-free animal conditions and han-
dled in accordance with the ethical and biosafety guide-
lines. This protocol was approved by the Institutional
Animal Care and Use Committee (IACUC NO. 09-0087)
of Seoul National University Hospital. In our pilot study,
we injected two types of GPT hydrogels (1.8 and 5.8
kPa) to confirm their in vivo durability in the subcutane-
ous region. Injected GPT hydrogels (1.8 kPa) degraded
completely within 1 week, whereas GPT hydrogels (5.8
kPa) remained intact (data not shown). We prepared
5 × 105 F3-effluc cells as pellets in centrifugation at
1,500 rpm for 5 min, which were then mixed with GPT
solution containing HRP. A dual hydrogel injection sys-
tem with two separate syringes filled with HRP (25 μg/
mL) dissolved in GPT solution A or in H2O2 (8 μg/mL)
dissolved in GPT solution B was used for in situ formation
of the cell-hydrogel complex. A 1-mL syringe was filled
with the mixture of F3-effluc cells and GPT solution A
(+HRP), and the other was filled with the F3-effluc/GPT
solution B (+H2O2) mixture. After each GPT solution was
filtered using a 200-nm pore-size syringe filter, they were
added into the dual injection syringe, and using a 26-
gauge needle, they were subcutaneously loaded into the
thigh of the nude mice.
To acquire the bioluminescence images, the mice (n = 3)
were anesthetized with 2% isoflurane at low rates of O2 gas
flow (1 L/min) via a nose cone after initial exposure inside
an induction chamber. For in vivo bioluminescence
imaging, D-luciferin was administered via intraperitoneal
injection at a dosage of 150 mg/kg. The bioluminescence
images were acquired using an IVIS-100 equipped with a
highly sensitive CCD camera (Caliper Life Sciences, Hop-
kinton, MA, USA). Bioluminescence light emission was
measured and integrated over 5 min. Region of interest
(ROI) signal intensity was measured in each representative
area and expressed as photon · s−1 · cm−2 · steradian−1.
IVIS-100 bioluminescence image parameter mode for
binning and f/stop was set up using values of 2 and 1,
respectively.
Immunohistochemistry analysis to investigate the in vivo
characteristics of implanted hydrogel-encapsulated
F3-effluc cells
Each sample resected from the cell-only, GPT 1.8 K, and
GPT 5.8 K groups was sectioned (8-μm-thick sections).
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room temperature for 20 min and were washed twice
for 10 min using PBS. To perform each step of the
blocking and permeabilization procedure simultaneously,
the mixture of 20% normal goat serum (NGS) and 0.5%
Triton X-100 in 0.01 M PBS was added to each slice for
20 min. The permeabilized samples were incubated with
primary antibodies specific for Tuj1 (Cell Signaling,
Danvers, MA, USA) and Ki-67 (Abcam, MA, USA) over-
night at 4°C. After each sample was rinsed three times
using 0.01 M PBS for 5 min, they were incubated with
fluorescence-labeled (Alexa Flour) secondary antibodies
for 60 min. The slices were mounted on cover slips with
an aqueous mounting medium supplemented with
4′,6-diamidino-2-phenylindole dihydrochloride (DAPI)
(Vector Laboratories Inc., Burlingame, CA, USA).
Statistical analysis
Data are shown as means ± standard error of the mean
(SEM) and were calculated using Student's t test. Statis-
tical significance was accepted at P values of less than 0.1.
Results
In situ cross-linkable GPT hydrogels and their mechanical
strength
The GPT hydrogels were formed via an enzyme-triggered
coupling reaction using HRP and H2O2. Figure 1a shows
the enzyme-mediated hydrogel formation of GPT conju-
gates. The phenol molecules of the GPT graft copolymer
are conjugated to each other via the carbon-carbon bond
at the ortho positions or via a carbon-oxygen bond be-
tween the carbon at the ortho position and the phenoxy
oxygen, by an enzyme-triggered oxidative reaction.
The measurement of elastic modulus (G′) of GPT
hydrogels in a time-controlled oscillatory mode with
different H2O2 concentrations revealed higher G′ values
(5,800 Pa) of the GPT hydrogels with higher H2O2 con-
centration (0.00075% w/w) because H2O2 plays as a cross-
linker in the enzyme-triggered cross-linking system. When
two different solutions (solution A contains HRP and so-
lution B contains H2O2) were rapidly mixed together with
a ratio of 1:1, the reaction mixture started to form GPT
hydrogel. Hereafter, we called the hydrogel with 1,800 Pa
(GPT 1.8 K) the soft hydrogel and that with 5,800 Pa
(GPT 5.8 K) the stiff hydrogel.
Morphological difference of F3-effluc cells in the soft and
the stiff GPT hydrogels
We used the F3-effluc cells that expressed stably the en-
hanced firefly luciferase (effluc) gene. F3-effluc cells showed
more than 85% purity, measured by MACS using
anti-CD90.1 microbeads [26]. After the same number
of F3-effluc cell was mixed with the soft GPT 1.8 K
or the stiff GPT 5.8 K, initial (day 0) phase contrastimages showed a distinct boundary of hardening hydrogel
matrix containing an evenly distributed F3-effluc cells. F3-
effluc cells incorporated within the three-dimensional
(3D) GPT 1.8 K were found to have a round shape on day
0 and continuously proliferated until day 2 (Figure 2a).
After day 4, the F3-effluc cells proliferated vigorously in
24-well plates, showing a neurosphere-like feature. The
F3-effluc cells in the stiff GPT 5.8 K group showed a rela-
tively lower cell growth rate than those in the soft GPT
1.8 K group (Figure 2b). F3-effluc cells proliferated con-
tinuously until day 8 in the stiff GPT 5.8 K as well as in
the soft GPT 1.8 K.
In vitro luciferase-based evaluation of cell growth rate in
the soft and the stiff hydrogels
We compared the proliferation rates of F3-effluc cells
within the soft GPT 1.8 K and the stiff GPT 5.8 K over
time by examining the luciferase activities of each cell/
hydrogel group. All the groups (cell-only, cell/GPT 1.8 K
complex, and cell/GPT 5.8 K complex) showed gradually
increasing proliferation rate until day 8 (Figure 3). How-
ever, the luciferase signals for the cell/hydrogel groups
were lower than those for the cell-only group at all time
points. To investigate whether the hydrogel matrix influ-
ences penetration of D-luciferin, the in vitro kinetics of
luciferase activity after D-luciferin administration was
examined in the soft GPT 1.8 K and the stiff GPT 5.8 K.
The F3-effluc cells reached a plateau 15 min after D-
luciferin addition in the cell-only group, and the F3-
effluc cells in the soft hydrogel time-to-peak extended to
25 min and the cells in the stiff GPT 5.8 K extended to
30 min (Additional file 1: Figure S1). D-Luciferin pene-
tration took more time to reach the cells in vitro.
In vivo bioluminescence kinetics of F3-effluc cells within
the soft and the stiff hydrogels in the mouse xenograph
model
The in vivo characteristics of F3-effluc cells incorporated
within the soft and the stiff hydrogels were examined on
the implanted xenograft in nude mice using a dual injec-
tion syringe. A dual hydrogel injection system is com-
posed of two separate syringes. One syringe contains
HRP dissolved in GPT solution, and the other syringe
contains H2O2 in GPT solution. F3-effluc cells were
loaded in the HRP-containing GPT solution, and then
the cells prepared in the dual hydrogel injector were im-
planted into the thigh of a nude mouse (Additional file 2:
Figure S2). The luciferase signals increased in the cell-only
and the F3-effluc/hydrogel complex implanted groups
until 21 days, showing higher proliferation of F3-effluc
cells within the soft GPT 1.8 K than within the stiff GPT
5.8 K or in the cell-only condition (Figure 4a). Cell growth
rate was about 1.8-fold higher in the F3-effluc/GPT 1.8 K
group than in the F3-effluc/GPT 5.8 K group.
Figure 1 Scheme of the in situ formation of gelatin-polyethylene glycol-tyramine (GPT) hydrogel. (a) The in situ formation of GPT
hydrogels occurred via an enzyme-mediated reaction using horseradish peroxidase (HRP) and H2O2 in an aqueous solution. (b) Elastic modulus
(G′) of the GPT hydrogels (3% w/w) was measured with different H2O2 concentrations (0.0038% to 0.0075% w/w).
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after D-luciferin administration, on day 0, the F3-effluc
cells in the cell-only condition showed the fastest time-to-
peak for luciferase signal by reaching a plateau at about
30 min. However, the time-to-peak in F3-effluc in the soft
GPT 1.8 K group was extended to 50 min, and the time-
to-peak in F3-effluc in the stiff GPT 5.8 K group was
slower (at 70 min) (Figure 4b).
Interestingly, the activity became very similar among
the three groups on day 8, showing times-to-peak of ap-
proximately 15 min for all groups (Figure 4b). On day 0,
extraction of the cell/hydrogel complex after several hoursof operation revealed the transparent cell/hydrogel com-
plex. It became opaque and pinkish due to proliferated
F3-effluc cells on day 8 (Figure 4c, left panel). Time-to-
peak was shortest in the cell-only group, and that of the
soft GPT 1.8 K group was shorter than that of the stiff
GPT 5.8 K group on day 0. But on days 8 and 21, they did
not show any difference (Figure 4c, right panel).
Immunohistochemistry of the extracted
F3-effluc/hydrogel complex
On day 21, after the bioluminescence imaging, the cell/
hydrogel complex was surgically resected from both thighs
Figure 2 Three-dimensional culture of human neural stem cells, F3-effluc, within the soft and stiff GPT hydrogels. (a) In the bottom of
the 24-well plate, 20 μL of cell/hydrogel was added (1:1 ratio of solutions A and B). The cell proliferation pattern of F3-effluc cells was compared
in the soft 1,800 Pa hydrogel (GPT 1.8 K) and the stiff 5,800 Pa hydrogel (GPT 5.8 K). F3-effluc cells proliferated inside GPT 1.8 K over time, and cells
started to migrate out from hydrogel mixture on day 4. Neurosphere-like stem cell clusters were also found on day 4. Scale bar = 10 μm. The
arrow represents boundary between the bottom of the well plate and cell/hydrogel mixture. (b) In contrast, F3-effluc cells in the stiff GPT 5.8 K
proliferated up to 8 day with lower degree than in the soft GPT 1.8 K. Scale bar = 10 μm.
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cells were compactly distributed in the cell-only group
(Figure 5a). In contrast, colonized cell population was ob-
served in the F3-effluc in the soft GPT 1.8 K and F3-effluc
in the stiff GPT 5.8 K sections. In the immunostaining of
each section using Tuj-1 (early neuronal marker) and Ki-
67 (proliferative marker) specific antibody, Ki-67 was weak
in the cell-only sections and was high in F3-effluc cells
within the soft GPT 1.8 K and the stiff GPT 5.8 K hydro-
gels. No Tuj-1-positive cells were observed in sections of
any group (Figure 5b).Discussion
High-water-content hydrogels with favorable biocom-
patibility have presented many benefits for various bio-
medical applications such as drug delivery and stem cell
therapy [27-34]. Being highly permeable to oxygen, nu-
trients, and metabolites, hydrogels can be used as artifi-
cial niches for paracrine signaling between cells and the
extracellular matrix. In particular, three-dimensional
hydrogels play an important role as scaffolds, supporting
grafted stem cells and minimizing local inflammation
and immunogenic reactions in tissue engineering and
Figure 3 In vitro luciferase activity versus time in F3-effluc cells
incorporated within the soft and stiff hydrogels. The same
number of F3-effluc cells within GPT 1.8 K and GPT 5.8 K was seeded
into the six-well plates. The two hydrogel groups and the cell-only
group were compared, and in all three groups, cell density increased
continuously up to day 8. *P value <0.1.
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the use of hydrogels may help grafted stem cells make
long-term retention in the injured area by preventing
grafted stem cells from uncontrollable migration to the
stem cell niche microenvironment.
In this study, gelatin-based biocompatible hydrogels
were used whose elasticity can be controlled by varying
the concentrations of the cross-linking reagent, and the
ability of grafted stem cell proliferation within different
types of hydrogels was evaluated in vivo as well as
in vitro. We focused mainly on the in vivo behavior of
neural stem cells encapsulated with the soft GPT 1.8 K
condition. For the future goal of neural stem cell-based
therapy in the brain, elasticity of less than 1 kPa, which
is similar to that of the intact brain tissue, would have
been ideal. However, hydrogels of less than 1 kPa de-
graded rapidly and was found to be unsuitable for cell
culture due to low cross-linking density in culture con-
ditions. Therefore, we chose the GPT 1.8 K that sustains
without degradation in culture conditions and possess
slightly harder properties than the brain tissue (0.1 to
1 kPa) and then compared its performance to the
stiff GPT 5.8 K [17-19].
In our results, the bright-field microscopy data showed
that cell growth rate of F3-effluc cells incorporated
within the soft GPT 1.8 K was higher than that of the
cells within the stiff GPT 5.8 K. Adherent F3-effluc cells
in 3D culture condition began to migrate out from the
hydrogel boundary around 4 days after mixing the cells
with the hydrogel of both types. We also observed
neurosphere-like features for F3-effluc cells inside the
soft GPT 1.8 K with dense, compact cell clusters at4 days. These were not observed in the GPT 5.8 K at
4 days, which demonstrated that the soft hydrogel envir-
onment might have been more suitable for in vitro cell
proliferation (Figure 2a,b). We found that luciferase
signals were lower in the hydrogel groups than in the
cell-only group and the luciferase activity in the cells in
the stiff GPT 5.8 K was lower than that in the soft GPT
1.8 K in the same conditions. We speculate that D-lucif-
erin is less able to penetrate the compact and stiff
hydrogel according due to the elastic properties in vitro.
Considering that the in vivo condition is more adverse
for the D-luciferin to penetrate the cell/hydrogel com-
plex, we investigated the in vivo kinetics luciferase activ-
ity after D-luciferin administration and found that the
cell-only group showed more rapidly increasing lucifer-
ase activity on day 0, compared with both hydrogel
groups. These results support our idea that the presence
of hydrogel makes D-luciferin reach the cells inside
more slowly. We suspect that the stiff GPT 5.8 K is less
permeable to the D-luciferin substrate. On day 0, time-
to-peak was the longest in the stiff GPT 5.8 K in vivo.
However, on day 8 and day 21, degradation of the im-
planted hydrogel associated with proliferating F3-effluc
cells induced similar kinetics of luciferase activity in
both types of hydrogel scaffolds in that D-luciferin pene-
tration was not different between the soft and the stiff
hydrogels even though experimental scale error bar was
high on day 0, possibly owing to initial injection tech-
niques or injection depth (Figure 4b,c).
Although the aforementioned in vivo D-luciferin kinetic
study showed a similar time-to-peak value between the
soft and stiff hydrogels on day 21, we observed the higher
proliferation of F3-effluc cells within the soft GPT 1.8 K,
demonstrating that the soft microenvironment (1.8 K Pa)
that is similar to the mechanical strength of the intact
brain is more suitable for neural stem cell growth com-
pared to the stiff environment (Figure 4a). Since the soft
GPT 1.8 K has higher water content and low cross-linking
density, in vivo degradation would have been more rapid
than in the stiff GPT 5.8 K and factors such as nutrients
and hormones would have better chance to reach the cells.
Our in vivo molecular imaging technique enabled us
to monitor survival and proliferation of grafted cells
paired with biomaterials such as poly-L-lactic acid (PLLA)
in a non-invasive manner in living subjects [38]. This
study was also the case with cell/hydrogel complexes
implanted to the nude mice. Image-based studies in the
tissue engineering field easily provide essential informa-
tion about how many scaffold-encapsulated cells were
implanted at the beginning and how long the implanted
cells could sustain within the scaffold in vivo. In particu-
lar, for cell-based therapies, such methodologies can be
used as a means to determine the optimal cell number
to be implanted.
Figure 4 (See legend on next page.)
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Figure 5 Immunostaining results from F3-effluc cells encapsulated within the hydrogel matrix. (a) Hematoxylin and eosin staining on day
21 showed a homogenous distribution in the cell-only group (left upper panel). A small quantity of the host cells was infiltrated into each hydrogel
(upper middle and right panel). A partially colonized cell mass (lower two panels) in the hydrogel was found in the soft GPT 1.8 K and the stiff
GPT 5.8 K groups. (b) Each section acquired from the resected cell mass was stained using different antibodies. The proliferated F3-effluc cells
from all groups did not show any Tuj1 (early neuronal marker) expression. In contrast, implanted cells within the hydrogels were highly stained
(red color) with the proliferative marker, Ki-67, compared to the cell-only group. The nucleus was counterstained with DAPI (blue color).
(See figure on previous page.)
Figure 4 In vivo bioluminescence imaging of implanted F3-effluc within hydrogel possessing different elasticities in nude mice. (a) A
dual injection syringe containing 1 × 106 F3-effluc cells with HRP and H2O2 solution was used to produce a rapid gel reaction in in vivo
environment. The bioluminescence images were acquired at different time points (0, 8, and 21 days) using an IVIS-100 imaging device (n = 3). Cell
growth in the soft GPT 1.8 K was greater compared with both the cell-only and the stiff GPT 5.8 K groups. *P value <0.1 (b) In vivo kinetics of luciferase
activity was conducted after D-luciferin administration in cell/hydrogel-injected nude mice. Bioluminescence signals were serially measured for 90 min
at intervals of 5 min in the same mice. (c) The transparent hydrogel containing F3-effluc cells was resected from the thigh of mouse on day 0.
The cell/hydrogel complex became pinkish with a large cell mass that proliferated within the complex on day 8. The initial time-to-peak on day
0 was different between the cell-only group and the soft and the stiff hydrogel groups. However, on day 8 and after, times-to-peak became
similar for the three groups.
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http://www.ejnmmires.com/content/4/1/61The in vivo optical imaging to examine the cell/hydro-
gel implantation has been reported by several groups,
who assessed the effectiveness of bioluminescence tech-
niques by monitoring viable stem cells within the hydro-
gel in vivo [39,40]. In this study, studies for evaluating
critical parameters such as the mechanical strength of
hydrogel were easily conducted in vivo by molecular optical
imaging techniques. We could determine which hydrogel
was more appropriate for more cells to survive and prolif-
erate in the cell/hydrogel implants.
Surface-functionalized hydrogels, such as the RGD-
cross-linked hydrogel, were introduced to enhance cell
proliferation [40-42]. The grafted stem cells distrib-
uted inside MMP-sensitive peptide-modified hydrogels
exhibited enhanced expression of early cardiac cell-
related transcription factor and induced cardiopro-
genitor differentiation [41]. RGD-modified hydrogel
mimicking the in vivo extracellular matrix structure
was applied to an animal model, showing functional
improvement in spinal cord injury [42]. Taking these
examples into consideration, hydrogel could be one of
the most attractive biomaterials in terms of biocom-
patibility and biodegradability. However, so as to
maximize the cell survival in vivo, we need to choose
the appropriate hydrogel among the wide variety avail-
able. Thus, the determination of the optimal elasticity
for a hydrogel is of great importance, and biolumines-
cence in vivo imaging was the study of choice in this
investigation. The in vivo characteristics of biomimetic
hydrogels of different elasticities could easily be evalu-
ated by in vivo molecular imaging. Using this invaluable
information from in vivo molecular imaging, hydrogel-
based cell implantation therapy will eventually enhance
the efficacy of regenerative therapy.Conclusions
This work establishes the efficacy of in vivo monitoring
of the viability of implanted neural stem cells, incorpo-
rated within different types of bioactive hydrogel. It
was found that the neural stem cells within GPT 1.8 K
(soft gel type) showed a higher proliferation rate than
those in GPT 5.8 K (stiff gel type), in subcutaneously
injected mice. From kinetic studies using a luciferase-
based optical imaging technique, different biolumines-
cence signal dynamics were found for the GPT 1.8 K
and GPT 5.8 K, both in vitro and in vivo. Our results
provide useful information to determine the desired
hydrogel elasticity or the optimal optical imaging con-
ditions for hydrogel-encapsulated implanted cells. The
developed methodology, based on in vivo imaging, will
help to enhance the therapeutic efficacy of stem cell
therapy by providing essential information for the treat-
ment of neurological disease.Additional files
Additional file 1: Figure S1. In vitro kinetic analysis of luciferase
activity after d-luciferin administration. The luciferase activity was
measured for 95 min at intervals of 5 min in F3-effluc cell-only, the soft
GPT 1.8 K/cell, and the stiff GPT 5.8 K/cell groups. The overall luciferase
intensity curve over time was a little different for the three cell groups.
Additional file 2: Figure S2. A dual hydrogel injection system was
adopted to implant the cell/hydrogel complex. Two separate syringes in
the dual hydrogel injector contain HRP dissolved in GPT solution and
H2O2 in GPT solution, respectively. Cells were loaded in the GPT solution
containing HRP. A dual hydrogel injector containing cells was implanted
into the thigh of a mouse.
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